Summary
One hundred twenty-seven adults with advanced hematologic malignancies received thiotepa 450–750 mg/m2, busulfan 10 or 12 mg/kg, and cyclophosphamide 120 or 150 mg/kg as a preparative regimen for autologous (86 patients) or allogeneic (41 patients) marrow transplantation. Early regimen-related toxicity (RRT) was scored according to the Seattle toxicity grading system. Grade 1–4 RRT occurred in 94% of the patients. Grade 3–4 RRT was noted in 19 patients (9% of the autologous and 27% of the allogeneic marrow recipients) and included 6% hepatic, 5% pulmonary, 3% renal, 2% mucosal, 2% bladder, 2% cardiac, and 1% CNS toxicity at the grade 3 or 4 level. No patient experienced life-threatening or fatal gastrointestinal or cutaneous toxicity. A stepwise logistic regression analysis suggested that the higher busulfan dose, Zubrod performance status of 2 or 3, and ten or more previous cycles of chemotherapy were factors predictive of grade 3–4 RRT. The regimen-related mortality for all patients was 8% (95% Cl 4–14%). The incidence and spectrum of RRT for this novel drug combination are similar to those reported for the standard preparative regimens. Heavily pretreated patients with poor performance status receiving the higher busulfan dose have a higher incidence of severe or fatal RRT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bearman SI, Appelbaum FR, Buckner CD et al. (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562–1568
Bearman SI, Appelbaum FR, Back A et al. (1989) Regimenrelated toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 7:1288–1294
Brodsky R, Topolsky D, Crilley P et al. (1990) Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol 13:221–225
Buckner CD, Clift RA, Appelbaum FR et al. (1992) A randomized study comparing two transplant regimens for CML in chronic phase (CP). Blood 80 [Suppl 1]:72a
Copelan EA, Biggs JC, Thompson JM et al. (1991) Treatment of acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 78:838–843
Cox DR, Snell EJ (1989) Analysis of binary data. Chapman and Hall, New York
Dimopoulos MA, Alexanian R, Przepiorka D et al. (1993) Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or peripheral blood stem cell transplantation in high-risk multiple myeloma. Blood 82:2324–2328
Essell JH, Thompson JM, Harman GS et al. (1992) Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 79:2784–2788
Geller RB, Myers S, Devine S et al. (1992) Phase-I study of busulfan, cyclophosphamide and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone Marrow Transplant 9:41–47
Jones RJ, Lee KSK, Beschorner WE et al. (1987) Veno-oc-clusive disease of the liver following bone marrow transplantation. Transplantation 44:778–783
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
McDonald GB, Sharma P, Matthews DE et al. (1984) Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatol 4:116–122
Miller CB, Hayashi RJ, Vogelsang GB et al. (1990) Aseptic shock syndrome after bone marrow transplantation (BMT). Blood 80 [Suppl 1]:140a
Miller C, Wagner JE, Vogelsang GB et al. (1992) A randomized trial of busulfan-cyclophosphamide (BU-CY) versus cyclophosphamide-total body irradiation (CY-TBI) as preparative regimen for patients with chronic myelogenous leukemia (CML). Blood 80 [Suppl 1]:291a
Nevill TJ, Barnett MJ, Klingemann H-G et al. (1991) Regimen related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 9:1224–1232
Peters WP, Henner WD, Grochow LB et al. (1987) Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47:6402–6406
Phillips GL, Shepherd JD, Barnett MJ et al. (1991) Busulfan, cyclophosphamide and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol 9:1880–1888
Przepiorka D, Ippoliti C, Ownby K et al. (1992) A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Blood 80 [Suppl 1]:337a
Przepiorka D, Nath R, Ippoliti C et al. (1993) A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide with autologous marrow transplantation for lymphoma. Blood 82 [Suppl 1]: 144a
Ratanatharathorn V, Karanes C, Lum LG et al. (1992) Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 9:49–55
Reece DE, Barnett MJ, Connors JM et al. (1993) Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 11:139–146
Robbins RA, Linder J, Stahl MG et al. (1989) Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 87:511–518
Santos GW, Tutschka PJ, Brookmeyer R et al. (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347–1353
Shulman HM, Hinterberger W (1992) Hepatic veno-occlusive disease — liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 10:197–214
Storb R (1987) Critical issues in bone marrow transplantation. Transplant Proc 19:2774–2781
Thomas ED, Buckner CD, Banaji M et al. (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49:511–533
Tutschka PJ, Copelan EA, Klein JP (1987) Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382–1388
Van der Jagt RHC, Appelbaum FR, Petersen FB et al. (1991) Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 8:211–215
Vaughan WP, Dennsison JD, Reed EC et al. (1991) Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 8:489–495
Wolff SN, Herzig RH, Fay JW et al. (1990) High-dose N,N′,N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase-I studies. Semin Oncol 17:2–6
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Przepiorka, D., Dimopoulos, M., Smith, T. et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicity. Ann Hematol 68, 183–188 (1994). https://doi.org/10.1007/BF01834364
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01834364